February 2003

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.

The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond.